Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations
- PMID: 26755905
- PMCID: PMC4697024
- DOI: 10.5114/pdia.2015.56097
Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations
Abstract
Introduction: According to available data, pruritus is a common symptom of psoriasis, however its characteristics and pathogenesis are not clearly understood.
Aim: The main aim of this study was to assess itching sensation among patients suffering from psoriasis, including its incidence and severity. All factors triggering and worsening pruritic symptoms were also carefully analyzed. The authors assessed the relationship of itch with body mass index (BMI) and severity of disease. Moreover, serum levels of interleukin 17 (IL-17) and IL-31 were analyzed in relation to Psoriasis Activity and Severity Index, BMI and severity of pruritus.
Material and methods: The study group consisted of 60 patients with plaque-type psoriasis. Analysis of impact of pruritus on the quality of life and worsening factors was based on the questionnaire. The severity of pruritus was assessed with the use of two independent scales. Serum IL-17 and IL-31 levels were measured in 30 patients suffering from psoriasis and in 10 healthy controls using immunoassay tests.
Results: 88.3% of analyzed patients complained of itch and the most common factor which exacerbated pruritus was stress (39.6%). Pruritus in psoriasis was independent of gender, illness duration and extent of skin lesions. The average intensity of pruritus was assessed as moderate and did not correlate significantly with BMI level, IL-17 and IL-31.
Conclusions: Since the pathogenesis of pruritus in psoriasis is not fully understood, further investigation in this area needs to be conducted. Pruritus may be considered as a characteristic feature of psoriasis and, besides the skin lesions, should be a target in dermatological treatment to improve patient's quality of life.
Keywords: Psoriasis Activity and Severity Index; body mass index; interleukin 17; interleukin 31; itch; pruritus; psoriasis.
Similar articles
-
Itching in patients suffering from psoriasis.Acta Dermatovenerol Croat. 2002 Dec;10(4):221-6. Acta Dermatovenerol Croat. 2002. PMID: 12588672
-
Itch in psoriasis: epidemiology, clinical aspects and treatment options.Clin Cosmet Investig Dermatol. 2009 Feb 19;2:9-13. doi: 10.2147/ccid.s4465. Clin Cosmet Investig Dermatol. 2009. PMID: 21436964 Free PMC article.
-
Pruritus in chronic plaque psoriasis: a questionnaire-based study of 230 Italian patients.Acta Dermatovenerol Croat. 2014;22(2):122-8. Acta Dermatovenerol Croat. 2014. PMID: 25102798
-
Interplay of Itch and Psyche in Psoriasis: An Update.Acta Derm Venereol. 2016 Aug 23;96(217):55-7. doi: 10.2340/00015555-2374. Acta Derm Venereol. 2016. PMID: 27282194 Review.
-
Psoriasis-associated itch: etiology, assessment, impact, and management.J Dermatolog Treat. 2020 Feb;31(1):18-26. doi: 10.1080/09546634.2019.1572865. Epub 2019 Jul 5. J Dermatolog Treat. 2020. PMID: 30663443 Review.
Cited by
-
Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences.Int J Mol Sci. 2023 Sep 29;24(19):14734. doi: 10.3390/ijms241914734. Int J Mol Sci. 2023. PMID: 37834183 Free PMC article. Review.
-
Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life.J Clin Med. 2022 Feb 25;11(5):1254. doi: 10.3390/jcm11051254. J Clin Med. 2022. PMID: 35268344 Free PMC article.
-
Immunotargets and Therapy for Prurigo Nodularis.Immunotargets Ther. 2022 Apr 26;11:11-21. doi: 10.2147/ITT.S316602. eCollection 2022. Immunotargets Ther. 2022. PMID: 35502157 Free PMC article. Review.
-
Evaluation of Serum Proinflammatory Cytokine IL-17A and Tight Junction Protein Claudin-1 in Psoriasis.Contrast Media Mol Imaging. 2022 Mar 7;2022:6092808. doi: 10.1155/2022/6092808. eCollection 2022. Contrast Media Mol Imaging. 2022. PMID: 35340911 Free PMC article.
-
Microbiota and IL-33/31 Axis Linkage: Implications and Therapeutic Perspectives in Atopic Dermatitis and Psoriasis.Biomolecules. 2023 Jul 10;13(7):1100. doi: 10.3390/biom13071100. Biomolecules. 2023. PMID: 37509136 Free PMC article. Review.
References
-
- Pogatzki-Zahn E, Marziniak M, Schneider G, et al. Chronic pruritus: targets, mechanisms and future therapies. Drug News Perspect. 2008;10:541–51. - PubMed
-
- Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol. 2011;11:420–7. - PubMed
-
- Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;2:3–11. - PubMed
-
- Tseng HW, Lin HS, Lam HC. Co-morbidities in psoriasis: a hospital-based case-control study. J Eur Acad Dermatol Venereol. 2013;27:1417–25. - PubMed
-
- Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. Br J Dermatol. 2004;151:1272–88. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials